The Public M&A and Life Sciences teams advised Pathos AI, Inc. (“Pathos”) on its definitive agreement with Rain Oncology Inc. (Nasdaq: RAIN) to acquire all outstanding shares of Rain through a tender offer for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share.
Following the tender offer closing, a wholly owned subsidiary of Pathos will be merged into Rain with Rain as the surviving entity of the merger.
The Goodwin team consisted of Mitchell Bloom, Robert Masella, Jean Lee, Will Stanton, Pat O’Brien, Matt Kane, Daniel Karelitz, Cecily Xi, Sarah Bock, Andre Amorim, Timothy Holahan, Lauren NuDelman, Matt Wetzel, Tim Worden, Luke Nauth, Catherine McCarty, Gina Jane Kim, Shane Albright, Jacqueline Klosek, Alexander Varond, Brian Mukherjee, Robert Fitzgerald, Caroline Bullerjahn and Nicole Osunsanmi.
For additional details on the merger, please read the press release.